Cargando…

Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer

BACKGROUND: Chronic inflammation has been suggested to favour prostate cancer (PCA) development. Interleukins (IL) represent essential inflammation mediators. IL-2, IL-7, IL-15 and IL-21, sharing a common receptor γ chain (c-γ), control T lymphocyte homeostasis and proliferation and play major roles...

Descripción completa

Detalles Bibliográficos
Autores principales: Mengus, Chantal, Le Magnen, Clémentine, Trella, Emanuele, Yousef, Kawa, Bubendorf, Lukas, Provenzano, Maurizio, Bachmann, Alexander, Heberer, Michael, Spagnoli, Giulio C, Wyler, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191336/
https://www.ncbi.nlm.nih.gov/pubmed/21943235
http://dx.doi.org/10.1186/1479-5876-9-162
_version_ 1782213637829558272
author Mengus, Chantal
Le Magnen, Clémentine
Trella, Emanuele
Yousef, Kawa
Bubendorf, Lukas
Provenzano, Maurizio
Bachmann, Alexander
Heberer, Michael
Spagnoli, Giulio C
Wyler, Stephen
author_facet Mengus, Chantal
Le Magnen, Clémentine
Trella, Emanuele
Yousef, Kawa
Bubendorf, Lukas
Provenzano, Maurizio
Bachmann, Alexander
Heberer, Michael
Spagnoli, Giulio C
Wyler, Stephen
author_sort Mengus, Chantal
collection PubMed
description BACKGROUND: Chronic inflammation has been suggested to favour prostate cancer (PCA) development. Interleukins (IL) represent essential inflammation mediators. IL-2, IL-7, IL-15 and IL-21, sharing a common receptor γ chain (c-γ), control T lymphocyte homeostasis and proliferation and play major roles in regulating cancer-immune system interactions. We evaluated local IL-2, IL-7, IL-15 and IL-21 gene expression in prostate tissues from patients with early stage PCA or benign prostatic hyperplasia (BPH). As control, we used IL-6 gene, encoding an IL involved in PCA progression. IL-6, IL-7 and IL-15 titres were also measured in patients' sera. METHODS: Eighty patients with BPH and 79 with early (1 to 2c) stage PCA were enrolled. Gene expression in prostate tissues was analyzed by quantitative real-time PCR (qRT-PCR). Serum IL concentrations and acute phase protein titres were evaluated by ELISA. Mann-Whitney, Wilcoxon and χ(2 )tests were used to compare IL gene expression and serum titers in the two groups of patients. Receiver operating characteristic (ROC) curves were constructed to evaluate the possibility to distinguish sera from different groups of patients based on IL titers. RESULTS: IL-2 and IL-21 gene expression was comparably detectable, with low frequency and at low extents, in PCA and BPH tissues. In contrast, IL-6, IL-7 and IL-15 genes were expressed more frequently (p < 0.0001, p = 0.0047 and p = 0.0085, respectively) and to significantly higher extents (p = 0.0051, p = 0.0310 and p = 0.0205, respectively) in early stage PCA than in BPH tissues. Corresponding proteins could be detected to significantly higher amounts in sera from patients with localized PCA, than in those from patients with BPH (p = 0.0153, p = 0.0174 and p = 0.0064, respectively). Analysis of ROC curves indicates that IL-7 (p = 0.0039), but not IL-6 (p = 0.2938) or IL-15 (p = 0.1804) titres were able to distinguish sera from patients with malignancy from those from patients with benign disease. Serum titres of C reactive (CRP), high mobility group B1 (HMGB1) and serum amyloid A (SAA) acute phase proteins were similar in both groups of patients. CONCLUSIONS: Expression IL-7 and IL-15 genes in prostate tissues and corresponding serum titres are significantly increased in patients with early stage PCA as compared with patients with BPH.
format Online
Article
Text
id pubmed-3191336
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31913362011-10-13 Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer Mengus, Chantal Le Magnen, Clémentine Trella, Emanuele Yousef, Kawa Bubendorf, Lukas Provenzano, Maurizio Bachmann, Alexander Heberer, Michael Spagnoli, Giulio C Wyler, Stephen J Transl Med Research BACKGROUND: Chronic inflammation has been suggested to favour prostate cancer (PCA) development. Interleukins (IL) represent essential inflammation mediators. IL-2, IL-7, IL-15 and IL-21, sharing a common receptor γ chain (c-γ), control T lymphocyte homeostasis and proliferation and play major roles in regulating cancer-immune system interactions. We evaluated local IL-2, IL-7, IL-15 and IL-21 gene expression in prostate tissues from patients with early stage PCA or benign prostatic hyperplasia (BPH). As control, we used IL-6 gene, encoding an IL involved in PCA progression. IL-6, IL-7 and IL-15 titres were also measured in patients' sera. METHODS: Eighty patients with BPH and 79 with early (1 to 2c) stage PCA were enrolled. Gene expression in prostate tissues was analyzed by quantitative real-time PCR (qRT-PCR). Serum IL concentrations and acute phase protein titres were evaluated by ELISA. Mann-Whitney, Wilcoxon and χ(2 )tests were used to compare IL gene expression and serum titers in the two groups of patients. Receiver operating characteristic (ROC) curves were constructed to evaluate the possibility to distinguish sera from different groups of patients based on IL titers. RESULTS: IL-2 and IL-21 gene expression was comparably detectable, with low frequency and at low extents, in PCA and BPH tissues. In contrast, IL-6, IL-7 and IL-15 genes were expressed more frequently (p < 0.0001, p = 0.0047 and p = 0.0085, respectively) and to significantly higher extents (p = 0.0051, p = 0.0310 and p = 0.0205, respectively) in early stage PCA than in BPH tissues. Corresponding proteins could be detected to significantly higher amounts in sera from patients with localized PCA, than in those from patients with BPH (p = 0.0153, p = 0.0174 and p = 0.0064, respectively). Analysis of ROC curves indicates that IL-7 (p = 0.0039), but not IL-6 (p = 0.2938) or IL-15 (p = 0.1804) titres were able to distinguish sera from patients with malignancy from those from patients with benign disease. Serum titres of C reactive (CRP), high mobility group B1 (HMGB1) and serum amyloid A (SAA) acute phase proteins were similar in both groups of patients. CONCLUSIONS: Expression IL-7 and IL-15 genes in prostate tissues and corresponding serum titres are significantly increased in patients with early stage PCA as compared with patients with BPH. BioMed Central 2011-09-26 /pmc/articles/PMC3191336/ /pubmed/21943235 http://dx.doi.org/10.1186/1479-5876-9-162 Text en Copyright ©2011 Mengus et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mengus, Chantal
Le Magnen, Clémentine
Trella, Emanuele
Yousef, Kawa
Bubendorf, Lukas
Provenzano, Maurizio
Bachmann, Alexander
Heberer, Michael
Spagnoli, Giulio C
Wyler, Stephen
Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title_full Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title_fullStr Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title_full_unstemmed Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title_short Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
title_sort elevated levels of circulating il-7 and il-15 in patients with early stage prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191336/
https://www.ncbi.nlm.nih.gov/pubmed/21943235
http://dx.doi.org/10.1186/1479-5876-9-162
work_keys_str_mv AT menguschantal elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT lemagnenclementine elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT trellaemanuele elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT yousefkawa elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT bubendorflukas elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT provenzanomaurizio elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT bachmannalexander elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT heberermichael elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT spagnoligiulioc elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer
AT wylerstephen elevatedlevelsofcirculatingil7andil15inpatientswithearlystageprostatecancer